

**Amendment #1
to RFP-NIH-NIAID-DAIDS-03-44**

"Development and Testing of a Modified Vaccinia Ankara (MVA) Vaccine"

Amendment to Solicitation No.: [NIH-NIAID-DMID-03-44](#)

Amendment No.: 1

Amendment Date: September 4, 2002

RFP Issue Date: August 15, 2002

Issued By: Jacqueline C. Holden
Senior Contracting Officer
NIH/NIAID
Contract Management Branch
6700-B Rockledge Drive
Room 2230, MSC 7612
Bethesda, Maryland 20892-7612

Point of Contact: [Phil Hastings](#), Contract Specialist

Name and Address of Offeror: To All Offerors

The above referenced solicitation is hereby amended as follows to respond to questions presented by recipients of this RFP:

Question 1. In support of a submission for the NIH (MVA) RFP, will the Centers for Disease Control provide measurements of neutralizing activity for various pre/post vaccination sera vs. variola virus?

Answer 1. CDC will provide, for all offerors awarded a contract, experimental support to evaluate variola neutralizing activity of (scientifically) selected pre and post vaccination sera. The extent of the support will be determined in conjunction with NIAID.

- Except as provided herein, all terms and conditions of this RFP remain unchanged and in full force and effect.
- The hour and date specified for receipt of offers REMAINS: **[September 30, 2002, 4:00 PM, EST](#)**.
- Offerors must acknowledge receipt of this [Amendment #1](#), on each copy of the proposal submitted.

Failure to receive your acknowledgment of this amendment may result in the rejection of your offer.

[Top](#) | [RFP-NIAID-DAIDS-03-44](#)

[NIAID Contracts Home](#) | [NIH RFP Directory](#) | [NIH Home](#)